Form 4: C4 Therapeutics Director Owen Hughes Acquires Stock Options

Director Owen Hughes acquired 32,500 stock options in C4 Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Owen Hughes, a director of C4 Therapeutics, Inc., acquired 32,500 stock options.
• The options have an exercise price of $4.05.
• The options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
• Following the transaction, Hughes directly owns 32,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock options being granted to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather a procedural event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service as a member of the Board, suggesting an expectation of ongoing involvement and contribution from Owen Hughes.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Stakeholder Impact

• The granting of stock options aligns the interests of the director with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates